



Supplementary Fig. 1. Anti-Pn IgE, symptom scores, and temperature drops prior to treatment are not significantly different between groups receiving either diluent or Bz. A Serum anti-Pn IgE at week 0 prior to treatment with diluent (Dil) or Bz. **B** Symptom scores and **C** body temperature changes measured during the initial challenge prior to treatment on week -3.



Supplementary Fig. 2. Prolonged treatment with Bz does not affect numbers of Pn-specific IgG, total IgG, and total IgE antibody secreting cells in the bone marrow or spleen. Pn-specific IgG and total IgG ASCs in the **A** BM and **B** SPL of Pn-allergic mice treated with either Bz or diluent (Dil) on week 22. Total IgE ASCs in the **C** BM and **D** SPL on week 10. To determine total IgE ASC numbers in the BM (shown in **C**), cells from BM hind-legs of two mice were pooled. Numbers of ASCs were normalized to the total number of cells enumerated in each pair of BM hind-legs or SPL of each mouse. Data represent one of three independent experiments for IgG ASCs (**A** and **B**) and one of two independent experiments for IgE ASCs (**C** and **D**). Error bars denote mean \pm SD. Sp-specific



Supplementary Fig. 3. Prolonged treatment of peanut-allergic mice with bortezomib does not affect populations of B220⁺CD19⁺, IgG1⁺, CD3⁺, and CD11c⁺ cells in the bone marrow or spleen. **A** B220⁺CD19⁺, **B** IgG1⁺, **C** CD3⁺, and **D** CD11c⁺ cells in the BM and SPL of peanut-allergic mice treated with intravenous bortezomib (Bz) or diluent (Dil) on week 22. Numbers of cells analyzed by FACS were normalized to the total numbers of cells enumerated in the BM hind-legs or SPL of each mouse, indicating the total number of each cell type per compartment. Data represent one of two independent experiments with 10-15 mice per group. Error bars denote mean \pm SD.